Double-Expressor Lymphoma — Trials

Double-Expressor Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

11 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 7
Recruiting: 3
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–11 of 11 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05600686	Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma	active not recruiting	Phase 2	24	University of California, DavisOTHER	1	Sep 28, 2026	clinicaltrials
NCT03984448	Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas	active not recruiting	Phase 2 / Phase 3	363	National Cancer Institute (NCI)NIH	1	Aug 4, 2026